Abdolkarim Sheikhi

Prof. Abdolkarim Sheikhi

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2008 in Cancer Research
Verified
Journal Article
Open access
PDF file
DSD. Robert Siemens
D. Robert Siemens
NHNianping Hu
Nianping Hu
ASAbdolkarim Sheikhi
Abdolkarim Sheikhi
ECEugene Chung
Eugene Chung
LFLisa J. Frederiksen
Lisa J. Frederiksen
CGCharles H. Graham
Charles H. Graham
The MHC class I chain-related (MIC) molecules play important roles in tumor immune surveillance through their interaction with the NKG2D receptor on natural killer and cytotoxic T cells. Thus, shedding of the MIC molecules from the tumor cell membrane represents a potential mechanism of escape from NKG2D-mediated immune surveillance. Tumor hypoxia is associated with a poor clinical outcome for cancer patients. We show that hypoxia contributes to tumor cell shedding of MIC through a mechanism involving impaired nitric oxide (NO) signaling. Whereas hypoxia increased MIC shedding in human prostate cancer cells, activation of NO signaling inhibited hypoxia-mediated MIC shedding. Similar to incubation in hypoxia, pharmacologic inhibition of endogenous NO signaling increased MIC shedding. Parallel studies showed hypoxia-mediated tumor cell resistance to lysis by interleukin 2–activated peripheral blood lymphocytes (PBL) and NO-mediated attenuation of this resistance to lysis. Inhibition of NO production also led to resistance to PBL-mediated lysis. Interference of MIC-NKG2D interaction with a blocking anti-MIC antibody abrogated the effect of hypoxia and NO signaling on tumor cell sensitivity to PBL-mediated lysis. Finally, continuous transdermal delivery of the NO mimetic glyceryl trinitrate (7.3 μg/h) attenuated the growth of xenografted MIC-expressing human prostate tumors. These findings suggest that the hypoxic tumor microenvironment contributes to resistance to immune surveillance and that activation of NO signaling is of potential use in cancer immunotherapy. [Cancer Res 2008;68(12):4746–53]

19 October 2014 in Journal of Molecular Neuroscience
Verified
Journal Article
Closed access
PDF file
AJA. Jafarzadeh
A. Jafarzadeh
MJM. Jamali
M. Jamali
RMR. Mahdavi
R. Mahdavi
HEH. A. Ebrahimi
H. A. Ebrahimi
HHH. Hajghani
H. Hajghani
HDH. Daneshvar
H. Daneshvar

12 September 2017
Verified
Journal Article
Open access
MRMohammad Rafiei
Mohammad Rafiei
FKFaezeh Kiani
Faezeh Kiani
FSFatemeh Sayehmiri
Fatemeh Sayehmiri
KSKourosh Sayehmiri
Kourosh Sayehmiri
ASAbdolkarim Sheikhi
Abdolkarim Sheikhi
MAMona Zamanian Azodi
Mona Zamanian Azodi
Background: The mouth cavity hosts various types of anaerobic bacteria including Porphyromonas gingivalis, which causes periodontal inflammatory diseases. P. gingivalis is a gram-negative oral anaerobe and is considered as a main etiological factor in periodontal diseases. Several studies have reported a relationship between P. gingivalis in individuals with periodontal diseases and a critical role of this bacterium in the pathogenesis of periodontal diseases. The present study aimed at estimating this probability using a meta-analysis.

30 December 2017 in Medical Journal of the Islamic Republic Of Iran
Verified
Journal Article
Open access
PDF file
MRMohammad Rafiei
Mohammad Rafiei
FKFaezeh Kiani
Faezeh Kiani
FSFatemeh Sayehmiri
Fatemeh Sayehmiri
KSKourosh Sayehmiri
Kourosh Sayehmiri
ASAbdolkarim Sheikhi
Abdolkarim Sheikhi
MAMona Zamanian Azodi
Mona Zamanian Azodi
Background: The mouth cavity hosts various types of anaerobic bacteria including Porphyromonas gingivalis, which causes periodontal inflammatory diseases. P. gingivalis is a gram-negative oral anaerobe and is considered as a main etiological factor in periodontal diseases. Several studies have reported a relationship between P. gingivalis in individuals with periodontal diseases and a critical role ...

9 February 2021 in Cancers
Verified
Journal Article
Open access
PDF file
Elisa ToffoliElisa Toffoli
Elisa Toffoli
ASAbdolkarim Sheikhi
Abdolkarim Sheikhi
Yannick D. HöppnerYannick D. Höppner
Yannick D. Höppner
Pita de KokPita de Kok
Pita de Kok
MYMahsa Yazdanpanah-Samani
Mahsa Yazdanpanah-Samani
TGTanja De Gruijl
Tanja De Gruijl
Natural Killer (NK) cells are innate immune cells with the unique ability to recognize and kill virus-infected and cancer cells without prior immune sensitization. Due to their expression of the Fc receptor CD16, effector NK cells can kill tumor cells through antibody-dependent cytotoxicity, making them relevant players in antibody-based cancer therapies. The role of NK cells in other approved and experimental anti-cancer therapies is more elusive. Here, we review the possible role of NK cells in the efficacy of various anti-tumor therapies, including radiotherapy, chemotherapy, and immunotherapy, as well as the impact of these therapies on NK cell function.

13 April 2016 in Cancer Biomarkers
Verified
Journal Article
Closed access
PDF file
AJA. Jafarzadeh
A. Jafarzadeh
HFH. Fooladseresht
H. Fooladseresht
MNM. Nemati
M. Nemati
ZAZ. Assadollahi
Z. Assadollahi
ASAbdolkarim Sheikhi
Abdolkarim Sheikhi
AGAbbas Ghaderi
Abbas Ghaderi
BACKGROUND: The CXCL10 receptor, CXCR3, is preferentially expressed on Th1 and NK cells. Therefore, CXCL10 acts as a chemoattractant for these cells. The CXCL10 receptor, CXCR3, is preferentially expressed on Th1 and NK cells. Therefore, CXCL10 acts